Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by TCI Wealth Advisors Inc.

TCI Wealth Advisors Inc. trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 45.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 600 shares of the medical equipment provider's stock after selling 493 shares during the period. TCI Wealth Advisors Inc.'s holdings in Intuitive Surgical were worth $297,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Global X Japan Co. Ltd. boosted its stake in Intuitive Surgical by 11.7% in the first quarter. Global X Japan Co. Ltd. now owns 51,682 shares of the medical equipment provider's stock valued at $25,597,000 after acquiring an additional 5,393 shares in the last quarter. Premier Path Wealth Partners LLC raised its holdings in shares of Intuitive Surgical by 1.4% in the first quarter. Premier Path Wealth Partners LLC now owns 2,824 shares of the medical equipment provider's stock worth $1,399,000 after buying an additional 39 shares during the last quarter. Johnson Investment Counsel Inc. raised its holdings in shares of Intuitive Surgical by 6.0% in the first quarter. Johnson Investment Counsel Inc. now owns 28,144 shares of the medical equipment provider's stock worth $13,939,000 after buying an additional 1,599 shares during the last quarter. Beacon Capital Management LLC raised its holdings in shares of Intuitive Surgical by 12.8% in the first quarter. Beacon Capital Management LLC now owns 202 shares of the medical equipment provider's stock worth $100,000 after buying an additional 23 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in shares of Intuitive Surgical by 2.9% in the first quarter. State of Alaska Department of Revenue now owns 41,789 shares of the medical equipment provider's stock worth $20,696,000 after buying an additional 1,170 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ISRG has been the subject of a number of research analyst reports. Barclays decreased their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Evercore ISI decreased their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. BTIG Research set a $560.00 price target on shares of Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. Royal Bank Of Canada decreased their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, Truist Financial decreased their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and an average target price of $588.95.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $515.91, for a total value of $96,991.08. Following the sale, the executive vice president now owns 5,224 shares in the company, valued at $2,695,113.84. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 215 shares of Intuitive Surgical stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $549.06, for a total transaction of $118,047.90. Following the completion of the sale, the senior vice president now owns 1,768 shares in the company, valued at approximately $970,738.08. This trade represents a 10.84% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,998 shares of company stock valued at $2,611,577. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 1.1%

ISRG traded up $5.73 on Monday, reaching $515.09. The stock had a trading volume of 1,217,351 shares, compared to its average volume of 1,675,816. Intuitive Surgical, Inc. has a 12-month low of $413.82 and a 12-month high of $616.00. The business's 50-day moving average price is $528.53 and its two-hundred day moving average price is $537.06. The company has a market cap of $184.62 billion, a P/E ratio of 75.53, a price-to-earnings-growth ratio of 5.40 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the previous year, the company earned $1.50 earnings per share. As a group, analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.